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a cost savings of $21,200 per year in 41 patients with
Type 2 diabetes. CONCLUSION: Control of diabetes as
measured by the HbA1c was signiﬁcantly better after 
the initiation of insulin glargine with beneﬁts including a
decreased overall frequency of hypoglycemia. Addition-
ally, insulin glargine may be a cost-effective alternative 
to increases in the dose or number of oral hypoglycemic
agents in patients with Type 2 diabetes. Conclusive evi-
dence on the efﬁcacy of insulin glargine will come from
larger cohort studies.
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OBJECTIVES: Although clinical trial data are often used
in economic models, they may not reﬂect real-world 
utilization and outcomes of therapy. To determine real-
world resource use and outcomes of diabetic foot ulcer
(DFU) care using Graftskin (a living bi-layered skin sub-
stitute) and to supplement clinical data for a DFU treat-
ment model, a medical record abstraction study was
conducted at 21 U.S. treatment centers that practice good
wound care (GWC). METHODS: Two physician samples
were recruited: a Graftskin sample (physicians who fre-
quently use and receive reimbursement for Graftskin 
in the treatment of DFUs), and a non-Graftskin sample
(physicians who treat DFU using GWC and who do not
receive reimbursement for using Graftskin). Separate
abstraction forms were developed for each sample, sent
by mail to the treatment centers, completed by center
staff, and returned via fax. The center received a small
honorarium per completed form. RESULTS: Twenty-one
centers and 166 cases (83 Graftskin and 83 GWC) were
included in the analysis. Graftskin patients had more
severe DFUs (21cm2) than those in the Graftskin pivotal
trial (2.97cm2), which compared GWC plus Graftskin to
GWC alone. In addition, Graftskin patients had more
severe DFUs than the GWC patients in this study 
(11cm2). The mean number of Graftskin applications was
much lower in this study (1.27 applications) than in the
Graftskin pivotal trial (3.9 applications). Moreover, in
this study, the incidence of severe adverse events was sig-
niﬁcantly lower with Graftskin (37%) than with GWC
(52%), even when controlling for ulcer severity (p =
0.006). CONCLUSION: In actual practice, the number
of Graftskin applications was considerably lower and
DFU severity was substantially higher than in the 
Graftskin pivotal clinical trial. These data were applied
to the DFU treatment model, which yielded improved
estimates of the real-world impact of utilizing Graftskin
versus GWC.
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OBJECTIVES: Medication adherence and compliance are
problems in young and elderly patients. With the increas-
ing number of prescribed drugs, compliance drops and
the number of adverse events increases. Furthermore,
elderly patients are likely to have several co-morbidities,
which could also affect their drug-consumption behavior
considerably. In this study, our objective was to evaluate
the compliance of anti-diabetic medication therapy in
subjects with type 2 diabetes mellitus who initiated treat-
ment with one of various oral anti-diabetic drugs or
insulin. METHODS: Data for this study spanned the
period January 1, 1995 to March 31, 2002 and were
obtained from the Pharmetrics Patient-Centric Database,
which is comprised of fully adjudicated medical and phar-
maceutical claims for over 29 million unique patients
from 52 health plans across the US. Patients with Type 2
diabetes mellitus (n = 199,000) were classiﬁed into mutu-
ally exclusive treatment groups based on the therapy ﬁrst
received during the period of observation. Compliance
rate was determined by the total number of days between
ﬁrst ﬁlled and last ﬁlled prescription plus days ﬁlled in the
last prescription, divided by last ﬁll date and the ﬁrst ﬁll
date plus a 90-day gap. RESULTS: The pioglitazone
group (n = 2,730) ranked the highest in compliance with
a mean of 85% (89% in the 55–64 age group) and a
median of 91% compared to a mean compliance of 62%
in the insulin group (n = 27,274) (P < 0.001) and 81% in
the metformin group (n = 52,469) (P = 0.001). Similar
results were found in newly diagnosed subjects. One-third
of all pioglitazone patients added a second line therapy
for diabetes compared to 43.9% on rosiglitazone (n =
4,068). CONCLUSION: Compliance to treatment
regimen for patients taking pioglitazone was higher than
for patients on other anti-diabetic medications.
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OBJECTIVES: Patient risk is identiﬁed by an increase in
healthcare cost, the occurrence of hospitalization or emer-
gency room (ER) event, and a decrease in time to hospi-
talization or ER event. The purpose of this research is 
to investigate factors associated with high-risk diabetic
patients based on claims data from the California Med-
